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Abstract
Aims In this article we present our experience with ra-
diofrequency ablation (RFA) in the treatment of 105 renal
tumors.
Materials and Methods RFA was performed on 105 renal
tumors in 97 patients, with a mean tumor size of 32 mm
(11–68 mm). The mean patient age was 71.7 years (range,
36–89 years). The ablations were carried out under ultra-
sound (n = 43) or CT (n = 62) guidance. Imaging follow-
up was by contrast-enhanced CT within 10 days and then at
6-monthly intervals. Multivariate analysis was performed
to determine variables associated with procedural outcome.
Results Eighty-three tumors were completely treated at a
single sitting (79%). Twelve of the remaining tumors were
successfully re-treated and a clinical decision was made not
to re-treat seven patients. A patient with a small residual
crescent of tumor is under follow-up and may require
further treatment. In another patient, re-treatment was
abandoned due to complicating pneumothorax and difﬁcult
access. One patient is awaiting further re-treatment. The
overall technical success rate was 90.5%. Multivariate
analysis revealed tumor size to be the only signiﬁcant
variable affecting procedural outcome. (p = 0.007, Pearson
v
2) Five patients had complications. There have been no
local recurrences.
Conclusion Our experience to date suggests that RFA is a
safe and effective, minimally invasive treatment for small
renal tumors.
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In recent years radiofrequency ablation (RFA) has contin-
ued to evolve into an effective image-guided tool for the
minimally invasive destruction of small-volume, discrete
tumors. While the vast majority of experience has been
gained in the treatment of hepatocellular carcinoma (HCC)
and colorectal metastases in the liver, recent attention has
turned to renal tumors [1–4]. Renal tumors represent 3% of
all human tumors [5] and the 5-year survival rate for RCC
has increased from 34% in 1954 to 62% in 1996 [6]. There
has also been a 126% increase in the incidence of renal cell
carcinoma in the United States since 1950 [6]. Both the
increased incidence and the improved survival are largely
attributable to the radiologic detection of early-stage dis-
ease [7]. In addition, despite other strategies, this detection
is largely serendipitous at cross-sectional imaging studies
for other symptomatology. Some series have suggested that
up to 85% of all renal tumors are in fact detected inci-
dentally [8]. The improved outcome from smaller-volume
tumors has been reﬂected by the TNM classiﬁcation
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DOI 10.1007/s00270-007-9090-xsystem, whereby the upper size limit for T1 tumors was
increased to 7 cm in 1997 [9] and a subgroup of discrete
tumors < 4 cm in diameter was classiﬁed as stage T1a,
which rarely metastasize [7].
A growing body of opinion has acknowledged the
morbidity and mortality of radical surgery for often small
and potentially low-grade tumors [10]. This has paved the
way for nephron-sparing surgery, however, partial
nephrectomy can be a more technically demanding pro-
cedure than standard nephrectomy and carries its own, not
insigniﬁcant, morbidity [11–13]. Laparoscopic partial
nephrectomy represents a further evolution in minimally
invasive therapies for small-volume renal cancer, however,
it remains a technically demanding and time-consuming
operation. Image-guided thermal ablation techniques
including RFA, cryotherapy, and microwave ablation are
now emerging as practical, safe, and effective ablative
tools.
RFA has been widely used in the treatment of small-
volume hepatic tumors. It achieves tumor destruction
through thermally induced coagulative necrosis at tem-
peratures of 60 to 110 C. In 1999, we initiated a program
for the percutaneous RF ablation of small (<4-cm) renal
tumors at our institution. This paper outlines our experi-
ence with procedural technique, complications, and onco-
logic outcomes.
Materials and Methods
In 1999, ethics committee approval was granted for the
commencement of a renal tumor RFA program. Inclusion
criteria for possible RFA included patients unﬁt for major
surgical intervention, or for whom the surgeon deemed that
resection would be problematic due to tumor location (in-
terpolar or deep-set positions), multifocal disease (n = 6),
or in the setting of a solitary kidney (n = 20). In only one
case in this series was RFA used to treat a tumor in the
setting of metastatic disease to the dorsal spine.
The patients attended for outpatient assessment,
including a clotting screen (INR £ 1.4 was sought) and
creatinine measurement and a review of their recent
radiologic staging. A degree of renal impairment did not
preclude treatment but was carefully monitored following
RFA. Fully informed consent was obtained. The decision to
treat was based on established CT criteria, namely, average
density >20 Hounsﬁeld units (HU) and enhancement of
>20 HU after contrast [14], with or without additional
criteria such as absence of fat and contour deformation [7].
At the time of reporting, we have treated 105 renal tu-
mors in 97 patients. The mean age of the patients was 71.7
years (range, 36–89 years). Sixty-ﬁve patients were male
and 32 were female. Although the majority of tumors
treated were small, on occasions tumors larger than 4 cm
were ablated (n = 12), according to individual clinical
indications. The mean tumor size was 32 mm (median, 30
mm; range, 11–68 mm).
The tumors were assessed for ultrasonographic visibility
and ease of access. Some of the lesions (n = 43) were
treated under ultrasound guidance but those that were more
difﬁcult to visualize with ultrasound or that were in close
proximity to bowel (n = 62) were treated with a combi-
nation of CT and ultrasound guidance. Most small-volume
cortical tumors lend themselves to ultrasound-guided
treatment in the prone oblique position, however, more
recently we have tended toward a combined ultrasound-
and CT-guided approach to absolutely conﬁrm probe po-
sition with respect to adjacent structures. An initial con-
trast-enhanced study was performed with 100 ml of
iodinated contrast medium (300 mg I/ml; Omnipaque; GE
Healthcare, UK) at a rate of 4.0 ml per second. The sub-
sequent CT-guided intervention was performed using small
(5-mm-collimation) diagnostic spiral acquisitions.
Eighty-six tumors were exophytic and 19 were intrapa-
renchymal or more centrally located. Tumors were deemed
exophytic when 25% or more of their diameter protruded
outside the cortical margin [15]. Twenty-three tumors were
located within the upper pole of the kidney, 33 were in the
lower pole, and 49 were categorized as ‘‘interpolar’’ in
location. Fifty-seven tumors were located in the left kidney
and 48 in the right.
Occasionally anterior interpolar tumors are closely
approximated to the gut and it has been our practice to
increase the safety margin around these tumors using
‘‘hydrodissection’’ with 5% dextrose solution ± air (nine
cases) (Figs. 1a–c). In these cases, the related retroperito-
neal space is needle-punctured and 250 to 750 ml of 5%
dextrose solution is instilled to displace the bowel, so
creating a safety margin for thermal ablation.
In the case of two larger tumors, embolization was
performed prior to RFA with Embospheres (500–700 lm;
Biosphere Medical, Paris) using a co-axial microcatheter
technique to selectively target tumor vascularity. Both tu-
mors that were pre-embolized in this cohort were >5 cm in
size, although a lower threshold has been suggested [16].
The renal, adrenal, and lumbar arteries were assessed for
accessory collateral supply and, if identiﬁed, were also
embolized to stasis. In one case additional coiling
(Embolization Microcoils Soft Platinum Type-C; Cook,
Denmark) of a ‘‘parasitized’’ retroperitoneal feeding vessel
was performed.
All patients receive 24 h of broad-spectrum intravenous
antibiotic cover with metronidazole (500 mg three times
daily) and cefuroxime (750 mg three times daily) followed
by a 10-day course of oral ciproﬂoxacin (500 mg twice
daily). At our hospital most RFA procedures have been
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vidual patient requirement), with midazolam and fentanyl
citrate (Sublimaze; Janssen-Cilag, Belgium; n = 67), al-
though more recently we have shifted toward general anes-
thesia for larger-volume or multifocal treatments (n = 38).
Two RFA systems have been employed in this series:
Tyco/Radionics (Boulder, CO, USA) single (n = 21) or
cluster (n = 37) needle probes with 3- and 2.5-cm exposed
tips, respectively, and RITA (Mountainview, CA, USA)
expandable needle probes (Starburst and Starburst XL;
n = 47) at the initial treatment. In the case of Tyco/Rad-
ionics needle probes, treatments were applied using an
impedance-regulated 200W generator (CC1 generator;
Tyco, Boulder, CO, USA) in 12-min aliquots for between
12 and 36 min. With the RITA probe, a time- and tem-
perature-regulated 150- or 200-W generator (models 1500
and 1500X; RITA) was used, aiming for a mean target
temperature of 105 C, for 3- to 5-cm treatment cycles,
depending on the size of the lesion. A thermal ‘‘track
ablation’’ was performed at the end of the treatment epi-
sode to reduce the potential risk of track seeding. Patients
were monitored for 4 h in the recovery area and then ob-
served overnight on a ward before being discharged home.
RFA was performed by one of two experienced interven-
tional radiologists (D.J.B., J.E.I.C.) and the technique and
probe, as outlined above, were chosen at the discretion of
the operator and were not related to tumor characteristics.
The overall follow-up period ranged from 1 to 76
months (mean, 16.7 months in surviving patients). Follow-
up assessment was by contrast-enhanced CT (reported by
one of the two operators: D.J.B. or J.E.I.C.) and treatment
adequacy determined by the area of nonenhancement with
respect to the tumor mass [15]. Careful comparison was
made with the most recent preprocedural imaging.
(Figs. 2a, b). Subsequent CT assessment was made at
approximately 6-monthly intervals. This involved precon-
trast imaging of the tumor followed by images of the
abdomen in arterial phase (35 s) and subsequent imaging of
the chest, abdomen, and pelvis in the portal venous phase
(65 to 70 s) after administration of 100 ml of iodinated
contrast medium (300 mg I/ml; Omnipaque; GE Health-
care, UK) at a rate of 4.0 ml per second, with a collimation
of 1.25 mm (Siemens Somatom Sensation 16-slice scanner;
Siemens AG, Medical Solutions, Germany). Residual tu-
mor was deﬁned as enhancing tumor remnants within the
volume of the lesion as appreciated at preprocedural
imaging (Fig. 3a, d). If the patient had signiﬁcant renal
impairment, then iso-osmolar contrast was used (Visip-
aque; GE Healthcare, UK) and in one case gadolinium-
enhanced MR (T1-weighted, breath-hold volume sequ-
ence) imaging was utilized.
Multivariate analysis was performed on the data to
determine any association between treatment variables
(namely, tumor size, imaging modality, probe type, central/
exophytic position, and polar location within the kidney)
and the likelihood of successful tumor ablation. Statistical
Package for the Social Sciences (SPSS, version 10.0)
software was used for the analysis.
Results
Eighty-three of 105 tumors were completely treated at a
single sitting. In ﬁve elderly patients with thin residual
crescentsofviabletumor,aclinicaldecisionwasmadenotto
re-treat. In one case of subtotal treatment, the patient pro-
ceeded to nephrectomy, and in another where contralateral
nephrectomyhadbeenperformedformultipleoncocytomas,
the decision was made not to pursue further intervention.
Fourteen tumors were re-treated, the majority under CT
guidance (n = 12), and one patient is awaiting re-treatment.
Fig. 1 Prone contrast-enhanced CT images illustrating the technique
of ‘‘hydrodissection.’’ a Image showing an exophytic renal tumor
lying in close proximity to the colon (C). b A needle has been
introduced into the perirenal space and 5% dextrose is being instilled.
c The 5% dextrose has created a safety margin (arrows) between the
tumor and adjacent colon. The tines of an expandable RFA probe can
be seen within the lesion to be treated
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ablated (one patient required two re-treatments for com-
plete tumor ablation). The overall technical success rate of
this cohort is therefore 95 of 105 tumors (90.5%). In one
case of an elderly patient with kyphoscoliosis, the re-
treatment procedure was complicated by pneumothorax
and abandoned due to difﬁcult subsequent access. One
patient had a persistent small residual area of tumor
enhancement that will be reassessed at interim CT, how-
ever, it is thought likely that further treatment will be re-
quired.
Tumor size was clearly predictive of complete treat-
ment, with all tumors <3.5 cm (n = 73) in size being suc-
cessfully ablated at a single treatment sitting barring two
cases where lesions proved difﬁcult to target. The mean
size of tumors completely ablated at a single sitting was 28
mm (range, 14–46 mm) and the mean size of those in
whom the initial treatment was subtotal was 41 mm (range,
18–68 mm). A statistically signiﬁcant association was seen
between a tumor size of £ 3 cm and complete treatment at
a single session (p = 0.007, Pearson v
2; odds ratio, 3.99).
Of the 22 subtotal treatments, 9 were ultrasound-guided
and 13 were performed with a combination of CT and
ultrasound guidance. No statistically signiﬁcant association
between imaging modality utilized during RFA and treat-
ment outcome was observed (p = 0.996).
No statistically signiﬁcant association was seen between
tumor location within the kidney, in terms of either whe-
ther it was central or exophytic (p = 0.222, Fisher’s exact
test) or whether it was upper, lower, or interpolar
(p = 0.823, Pearson v
2) and successful tumor ablation at
ﬁrst sitting. Similarly, there was no association observed
between the type of probe used for RFA (single, cluster, or
expandable) and a successful initial outcome (p = 0.538,
Pearson v
2).
In this series, there was an overall complication rate of 5
of 120 treatment episodes (4.2%; 3 CT-guided, 2 ultra-
sound-guided). One patient developed profuse but self-
limiting hematuria. Another patient, in whom a scoliotic
deformity and a renal hematoma had complicated the
procedure, sustained a thermal injury to the duodenum that
required laparotomy and repair. He has subsequently made
a full recovery. A further patient was found to have mod-
erate hydronephrosis due to a proximal ureteric stricture on
a follow-up CT approximately 4 months post-RFA. This
was treated by temporary placement of a ureteric stent.
Two of the ﬁve complications occurred at second treat-
ments. In one case, the re-treatment was performed under
CT guidance in the prone-oblique position but complicated
by a marked kyphoscoliotic deformity. This led to poor
visualization of the upper pole target tumor and resulted in
a pneumothorax that was treated by simple chest tube
drainage. A further patient with a scoliosis and a 2.5-cm,
deeply set tumor developed a calyceal leak and subsequent
urinoma, which were treated by percutaneous drainage and
placement of a temporary ureteric stent. Of note, three of
the ﬁve complications occurred in the setting of marked
scoliotic deformity.
Within our follow-up study group there have been 13
deaths to date. Six of these were from completely unrelated
pathologies, namely, chronic lymphatic leukemia (two
cases), mesothelioma, obstructive airways disease, myo-
cardial infarction, and cholangitis. The cause of death was
not investigated or records were unobtainable in six cases,
however, follow-up imaging within 6 months of death had
demonstrated no recurrent or metastatic disease in these
patients. One death occurred due to disseminated meta-
static disease in a patient with von Hippel-Lindau disease
Fig. 2 a Contrast-enhanced CT revealing a small exophytic tumor
arising from the lower pole of the right kidney. b Contrast-enhanced
CT performed 3 days after RFA shows a typical wedge-shaped area of
nonenhancement, involving the tumor and immediately adjacent
cortex. This appearance indicates coagulative necrosis and hence a
completely treated lesion
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for renal cell carcinoma. She had three small tumors in her
remaining kidney, which were treated with RFA at a single
sitting. The patient was offered a second nephrectomy but
declined on the grounds that she did not wish to become
dialysis-dependent. At follow-up, a further metachronous
renal tumor became apparent and was successfully ablated.
This patient subsequently developed disseminated metas-
tases and died. In this case it was impossible to determine
which of the renal tumors had metastasized. One further
patient (a 78-year-old woman) developed lung metastases
under follow-up. She had undergone previous contralateral
nephrectomy for a large clear cell carcinoma 6 months
prior to RFA of a 2.5-cm tumor in the remaining kidney.
Small lung metastases were seen on a CT performed 3
months after RFA. There have been no other cases of
metastatic disease and no local recurrences.
Discussion
In recent years a number of groups have studied the use of
RFA in the management of small renal tumors [1, 2]. We
have reviewed our experience since 1999 in the treatment
of a large cohort of 105 renal tumors with regard to tech-
nical success, complications, and midterm oncologic efﬁ-
cacy.
The overall technical success rate for the procedure in
this series was 95 of 105 tumors (90.5%). This is compa-
rable with the results of Gervais et al. [1], who reported a
complete tumor necrosis rate of 90%. Matsumoto et al. [2]
pooled data from three major North American urological
centers in their report on the treatment outcome for 109
tumors and reported an overall technical success rate of
100%, with only two patients requiring re-treatment for
completion of the ablation. These procedures were carried
out percutaneously in 63 cases and at laparoscopy in 46
cases. This outcome may be explained in part by the small
tumor size in this report, which ranged from 0.8 to 4.7 cm
(mean, 2.4 cm). This compares to a mean tumor size of 3.2
cm in both this study and the series of Gervais et al. [1].
This cohort of 105 tumors has permitted multivariate
analysis of the factors likely to predict successful outcome.
It has been widely reported that exophytic tumors are more
amenable to thermal ablation, likely due to their smaller
‘‘vascular pedicle’’ with the underlying renal parenchyma
[1]. We utilised Gervais’ deﬁnition [15] of central and
exophytic tumors, yielding 19 central and 86 exophytic
tumors in this series, but we could not conﬁrm a statisti-
cally signiﬁcant association between tumor location and
Fig. 3 a Axial CT image of a 3-cm
exophytic right interpolar renal tumor prior
to RFA. b Ten days following RFA,
contrast-enhanced CT reveals that the
majority of the lesion is nonenhancing,
consistent with necrosis, but there is a
residual crescent of enhancing tumor within
the medial aspect of the lesion (arrow). c
One week after re-treatment of the residual
crescent of tumor, the whole lesion is
nonenhancing, in addition to a wedge-shaped
area of adjacent cortex. This is consistent
with complete necrosis of the tumor. d Five
years post RFA: the lesion shows typical
involution, with dispersal into the perirenal
fat (arrow). There is no evidence of tumor
recurrence
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regarding polar tumor location (23 upper pole, 33 lower
pole, and 49 interpolar), no signiﬁcant association with
outcome was conﬁrmed (p = 0.823, Pearson v
2). In addi-
tion, we found no signiﬁcant association between probe
type (cluster, single, expandable) and likelihood of com-
plete tumor ablation (p = 0.996, v
2). Logistic regression
revealed that the only statistically signiﬁcant variable
associated with successful outcome was tumor size. A tu-
mor size of £ 3 cm was associated with complete treat-
ment at a single session (p = 0.007, Pearson v
2; odds ratio,
3.99).
All 105 tumors have been treated by one of two oper-
ators (D.J.B., J.E.I.C.), in 43 cases with ultrasound guid-
ance alone and in 62 instances using CT guidance
combined with adjunctive ultrasound to facilitate probe
placement. It has been our experience that the latter tech-
nique expedites tumor treatment and increases operator
certainty with regard to the position of closely related bo-
wel loops, particularly during the use of expandable,
multitined probes.
Of the initial treatments, 3 of 105 (2.9%) incurred
complications. This parallels other large series such as that
of Matsumoto et al. [2], who, in their series of 109 tumors,
experienced a complication rate of 2.8%. Gervais et al. [1]
incurred 4 major complications in the treatment of 100
tumors. Contrary to the ﬁndings in that series, we did not
encounter signiﬁcant perirenal hemorrhage. In one case,
there was brisk but self-limiting hematuria and in another,
a temporary ureteric stricture, related to a lower pole tumor
treatment, was managed by temporary ureteric stenting. In
the third case, the target tumor was in the ‘‘deeply set’’
kidney of a patient with a scoliotic deformity. An initial
biopsy caused a moderate hematoma resulting in some
obscuration of the tumor for the purposes of probe place-
ment. The patient re-presented 3 days following treatment
and CT revealed a contained retroperitoneal duodenal
perforation, which was immediately repaired at laparot-
omy. We have now changed our practice such that when
biopsy is required, the RF needle is usually placed prior to
biopsy to ensure good probe position. This avoids obscu-
ration of the tumor by postbiopsy hematoma.
Two further complications occurred in the re-treatment
group, thereby yielding an overall complication rate of 5 of
120 treatment episodes (4.2%) but resulting in a higher
complication rate, 2 of 14 (14%), among this subset. In one
case, a patient with scoliosis, a calyceal leak caused a
urinoma that was managed by drainage and ureteric
stenting. In the second case, re-treatment of a poorly visible
tumor at the upper pole of the kidney was attempted under
ultrasound and CT guidance. This patient had a signiﬁcant
scoliotic deformity; attempted probe placement resulted in
a pneumothorax and the procedure had to be abandoned. It
is notable that three of these ﬁve overall complications
occurred in scoliotic patients when attempting to treat tu-
mors in the more poorly accessible, or ‘‘deep-set’’ kidney.
The case remains that RFA is an in situ technique,
reliant on devascularization of the tumor, as conﬁrmed by
nonenhancement at postprocedural CT to determine treat-
ment adequacy. No cases of late local recurrence have been
encountered and the authors believe that this is attributable
to meticulous postprocedural imaging assessment with the
use of multidetector CT and careful multiplanar assess-
ment.
The use of nonenhancement of the treated tumor and
peritumoral changes along with ablative changes to the
adjacent cortex as surrogates of treatment adequacy has
been criticized. This has, however, been borne out by the
steady involution of the treated tumors in this series under
CT follow-up. In 22 cases, incomplete treatment was evi-
denced by residual enhancing tumor ‘‘crescents,’’ and
secondary ablations were successfully performed in 12 of
these cases. A recent study by Michaels et al. [17] sug-
gested that residual viable tumor was present in all 20 re-
sected small-volume renal tumors on the basis of
hematoxylin and eosin staining and in 4 of 5 of the most
recent tumors on nicotinamide adenine dinucleotide
(NADH) diaphorase staining. There has been some criti-
cism of the adequacy of the RF treatment cycles used by
these authors, where the mean treatment time was 9.1 min.
In addition, hematoxylin and eosin staining has been
repeatedly criticized as an inadequate determinant of
thermally induced cell death [18]. Our mid- to long-term
case follow-up has also demonstrated steady involution of
the vast majority of treated lesions, and to date, with a
mean follow-up of 18 months, no revascularization of
treated tumors has been detected.
This patient cohort has been actively followed up, with
approximately 6-monthly CT surveillance over a period of
1 to 76 months. Thirteen patients have died, yielding a
mean follow-up among the survivors of 16.7 months. Only
two patients have developed metastatic renal cancer. One
patient suffered from von Hippel Lindau syndrome and had
undergone a previous nephrectomy. She refused a further
nephrectomy and proceeded to RFA of three renal tumors
in the remaining kidney. A fourth metachronous tumor was
subsequently treated. She presented approximately 18
months after the initial RFA treatment with disseminated
metastatic disease. Postmortem suggested new ‘‘interval’’
disease within the remnant kidney. In the other case,
nephrectomy for a 7-cm tumor had been carried out 6
months prior to a referral for RFA of a new 3-cm tumor in
the contralateral kidney. RFA for this second lesion was
successful, but at CT 3 months after RFA, a lung base
metastasis was noted. It remains indeterminate as to whe-
ther this related to the earlier larger tumor or the smaller
D. J. Breen et al.: Renal RFA in 105 Tumors 941
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natural history of RCC, the former seems more likely.
The imaging diagnosis of renal tumors has been
repeatedly shown to be more accurate than biopsy [19, 20]
due to false-negative specimens. However, even with
careful CT radiologic technique, it remains the case that a
proportion (~10%–15%) of resected or ablated lesions will
prove to be benign in nature such as fat-poor angiomyo-
lipomas and oncocytomas [7]. The lack of biopsy data in
this series could be considered a limitation of this study,
however, it could be argued that the inclusion of a small
number of benign lesions does not invalidate the results of
the technical efﬁcacy of the procedure with regard to tumor
necrosis. As commented upon by Matsumoto et al. [2],
even benign tumors such as oncocytomas have the poten-
tial to recur locally. Some authors would argue that with
the increasing detection of small renal tumors, which may
not be easily characterized at CT, there is an increasing role
for preprocedural percutaneous biopsy [21].
As yet there are few published long-term outcome data
for ablative techniques. In one recent study [22]o f1 6
biopsy-proven RFA cases with a minimum of 4 years’
follow-up, 5 patients died under surveillance and the
remainder were well, with no tumor recurrence. This
experience concurs with our accruing follow-up data.
Conclusion
These interim results in 105 tumors appear to conﬁrm the
efﬁcacy of RFA but formal 5-year follow-up data are
awaited. There does, however, appear to be a real place for
the image-guided ablation of sub-4-cm renal tumors in
patients who are less suitable for surgical resection.
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